Journey Medical Corp DERM
NasdaqSmall CapHealthcare
13F Pro quality score
Rank #2,801 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reading the latest SEC filing…
13F Pro quality score
Rank #2,801 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Journey Medical Corp (DERM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DERM at 16.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,801 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (3.6) and earnings quality (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Journey Medical Corp reports quarterly revenue of $18.5M, net income of $-312.0K, an operating margin of 2.5%. DERM trades on the Nasdaq exchange and files with the SEC under CIK 1867066. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DERM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Journey Medical Corp directly from SEC EDGAR.